Effector T cell resistance to suppression and stat3 signaling during the development of human type 1 diabetes

Journal of Immunology

Volumn 201, Issue 4, 2018, Pages 1144-1153

  Ihantola, Emmi Leena ^a   Viisanen, Tyyne ^a   Gazali, Ahmad M ^a   Näntö Salonen, Kirsti ^b   Juutilainen, Auni ^a,c   Moilanen, Leena ^c   Rintamäki, Reeta ^c   Pihlajamäki, Jussi ^a,c   Veijola, Riitta ^d   Toppari, Jorma ^b,e   Knip, Mikael ^f,g,h,i   Ilonen, Jorma ^b,e   Kinnunen, Tuure ^a,j  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ FOLKHÄLSAN RESEARCH CENTER   (Finland)

^j Pihlajalinna Medical Centre Eastern Finland   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ACTIVATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTIBODY PRODUCTION; CELL CULTURE; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PRESCHOOL CHILD; REGULATORY T LYMPHOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODY FORMATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 85051278007     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1701199     Document Type: Article

References (38)

1. Bluestone, J. A., K. Herold, and G. Eisenbarth. 2010. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464: 1293-1300.
2. Siljander, H. T. A., S. Simell, A. Hekkala, J. Lähde, T. Simell, P. Vähäsalo, R. Veijola, J. Ilonen, O. Simell, and M. Knip. 2009. Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 58: 2835-2842.
3. Ziegler, A. G., M. Rewers, O. Simell, T. Simell, J. Lempainen, A. Steck, C. Winkler, J. Ilonen, R. Veijola, M. Knip, et al. 2013. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309: 2473-2479.
4. You, S., M. Belghith, S. Cobbold, M.-A. Alyanakian, C. Gouarin, S. Barriot, C. Garcia, H. Waldmann, J.-F. Bach, and L. Chatenoud. 2005. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54: 1415-1422.
5. D'Alise, A. M., V. Auyeung, M. Feuerer, J. Nishio, J. Fontenot, C. Benoist, and D. Mathis. 2008. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc. Natl. Acad. Sci. USA 105: 19857-19862.
6. Schneider, A., M. Rieck, S. Sanda, C. Pihoker, C. Greenbaum, and J. H. Buckner. 2008. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 181: 7350-7355.
7. Lawson, J.M., J. Tremble, C. Dayan, H. Beyan, R. D. G. Leslie,M. Peakman, and T. I. M. Tree. 2008. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154: 353-359.
8. Venigalla, R. K., T. Tretter, S. Krienke, R. Max, V. Eckstein, N. Blank, C. Fiehn, A. D. Ho, and H. M. Lorenz. 2008. Reduced CD4+,CD25-T cell sensitivity to the suppressive function of CD4+,CD25high,CD127-/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 58: 2120-2130.
9. Schneider, A., S. A. Long, K. Cerosaletti, C. T. Ni, P. Samuels, M. Kita, and J. H. Buckner. 2013. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci. Transl. Med. 5: 170ra15.
10. Wehrens, E. J., G. Mijnheer, C. L. Duurland, M. Klein, J. Meerding, J. van Loosdregt, W. de Jager, B. Sawitzki, P. J. Coffer, B. Vastert, et al. 2011. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Blood 118: 3538-3548.
11. Haufe, S., M. Haug, C. Schepp, J. Kuemmerle-Deschner, S. Hansmann, N. Rieber, N. Tzaribachev, T. Hospach, J. Maier, G. E. Dannecker, and U. Holzer. 2011. Impaired suppression of synovial fluid CD4+CD25-T cells from patients with juvenile idiopathic arthritis by CD4+CD25+ Treg cells. Arthritis Rheum. 63: 3153-3162.
12. Goodman, W. A., A. D. Levine, J. V. Massari, H. Sugiyama, T. S. McCormick, and K. D. Cooper. 2009. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 183: 3170-3176.
13. Mercadante, E. R., and U. M. Lorenz. 2016. Breaking free of control: how conventional T cells overcome regulatory T cell suppression. Front. Immunol. 7: 193.
14. Goodman, W. A., A. B. Young, T. S. McCormick, K. D. Cooper, and A. D. Levine. 2011. Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 186: 3336-3345.
15. Trinschek, B., F. Luessi, J. Haas, B.Wildemann, F. Zipp, H.Wiendl, C. Becker, and H. Jonuleit. 2013. Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis. [Published erratum appears in 2013 PLoS One 8.] PLoS One 8: e77634.
16. Hunter, C. A., and S. A. Jones. 2015. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16: 448-457.
17. Tanaka, T., M. Narazaki, and T. Kishimoto. 2012. Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 52: 199-219.
18. Hundhausen, C., A. Roth, E. Whalen, J. Chen, A. Schneider, S. A. Long, S. Wei, R. Rawlings, M. Kinsman, S. P. Evanko, et al. 2016. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci. Transl. Med. 8: 356ra119.
19. Ilonen, J., A. Hammais, A.-P. Laine, J. Lempainen, O. Vaarala, R. Veijola, O. Simell, and M. Knip. 2013. Patterns of b-cell autoantibody appearance and genetic associations during the first years of life. Diabetes 62: 3636-3640.
20. Hoffmann, P., R. Eder, T. J. Boeld, K. Doser, B. Piseshka, R. Andreesen, and M. Edinger. 2006. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 108: 4260-4267.
21. Putnam, A. L., T. M. Brusko, M. R. Lee, W. Liu, G. L. Szot, T. Ghosh, M. A. Atkinson, and J. A. Bluestone. 2009. Expansion of human regulatory Tcells from patients with type 1 diabetes. Diabetes 58: 652-662.
22. Yang, J., M. O. Brook, M. Carvalho-Gaspar, J. Zhang, H. E. Ramon, M. H. Sayegh, K. J. Wood, L. A. Turka, and N. D. Jones. 2007. Allograft rejection mediated by memory T cells is resistant to regulation. Proc. Natl. Acad. Sci. USA 104: 19954-19959.
23. Afzali, B., P. J. Mitchell, C. Scottà, J. Canavan, F. C. Edozie, H. Fazekasova, G. M. Lord, S. John, L. D. Barber, M. P. Hernandez-Fuentes, et al. 2011. Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells. Am. J. Transplant. 11: 1734-1742.
24. Bhela, S., C. Kempsell, M. Manohar, M. Dominguez-Villar, R. Griffin, P. Bhatt, P. Kivisakk-Webb, R. Fuhlbrigge, T. Kupper, H. Weiner, and C. Baecher-Allan. 2015. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J. Immunol. 194: 2180-2189.
25. Acosta-Rodriguez, E. V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8: 639-646.
26. Morita, R., N. Schmitt, S.-E. Bentebibel, R. Ranganathan, L. Bourdery, G. Zurawski, E. Foucat, M. Dullaers, S. Oh, N. Sabzghabaei, et al. 2011. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34: 108-121.
27. Hagness, M., K. Henjum, J. Landskron, K.W. Brudvik, B. A. Bjørnbeth, A. Foss, K. Taskén, and E. M. Aandahl. 2012. Kinetics and activation requirements of contact-dependent immune suppression by human regulatory T cells. J. Immunol. 188: 5459-5466.
28. Xu, X., Y. Shi, Y. Cai, Q. Zhang, F. Yang, H. Chen, Y. Gu, M. Zhang, L. Yu, and T. Yang. 2013. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLoS One 8: e79858.
29. Alnek, K., K. Kisand, K. Heilman, A. Peet, K. Varik, and R. Uibo. 2015. Increased blood levels of growth factors, proinflammatory cytokines, and Th17 cytokines in patients with newly diagnosed type 1 diabetes. PLoS One 10: e0142976.
30. Waugh, K., J. Snell-Bergeon, A. Michels, F. Dong, A. K. Steck, B. I. Frohnert, J. M. Norris, and M. Rewers. 2017. Increased inflammation is associated with islet autoimmunity and type 1 diabetes in the diabetes autoimmunity study in the young (DAISY). PLoS One 12: e0174840.
31. Chen, Y.-L., Y.-C. Qiao, Y.-H. Pan, Y. Xu, Y.-C. Huang, Y.-H. Wang, L.-J. Geng, H.-L. Zhao, and X.-X. Zhang. 2017. Correlation between serum interleukin-6 level and type 1 diabetes mellitus: a systematic review and meta-analysis. Cytokine 94: 14-20.
32. Herrath, J., M. Müller, P. Amoudruz, P. Janson, J. Michaëlsson, P. T. Larsson, C. Trollmo, S. Raghavan, and V. Malmström. 2011. The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur. J. Immunol. 41: 2279-2290.
33. Honkanen, J., J. K. Nieminen, R. Gao, K. Luopajarvi, H. M. Salo, J. Ilonen, M. Knip, T. Otonkoski, and O. Vaarala. 2010. IL-17 immunity in human type 1 diabetes. J. Immunol. 185: 1959-1967.
34. Marwaha, A. K., S. Q. Crome, C. Panagiotopoulos, K. B. Berg, H. Qin, Q. Ouyang, L. Xu, J. J. Priatel, M. K. Levings, and R. Tan. 2010. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. 185: 3814-3818.
35. Ferraro, A., C. Socci, A. Stabilini, A. Valle, P. Monti, L. Piemonti, R. Nano, S. Olek, P. Maffi, M. Scavini, et al. 2011. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60: 2903-2913.
36. Kenefeck, R., C. J. Wang, T. Kapadi, L. Wardzinski, K. Attridge, L. E. Clough, F. Heuts, A. Kogimtzis, S. Patel, M. Rosenthal, et al. 2015. Follicular helper T cell signature in type 1 diabetes. J. Clin. Invest. 125: 292-303.
37. Viisanen, T., E.-L. Ihantola, K. Näntö-Salonen, H. Hyöty, N. Nurminen, J. Selvenius, A. Juutilainen, L. Moilanen, J. Pihlajamäki, R. Veijola, et al. 2017. Circulating CXCR5+PD-1+ICOS+ follicular T helper cells are increased close to the diagnosis of type 1 diabetes in children with multiple autoantibodies. Diabetes 66: 437-447.
38. Buckner, J. H., and G. T. Nepom. 2016. Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes. J. Autoimmun. 71: 44-50.